Literature DB >> 626493

Treatment of experimental Staphylococcus aureus endocarditis: comparison of cephalothin, cefazolin, and methicillin.

J Carrizosa, J Santoro, D Kaye.   

Abstract

The effectiveness of cefazolin in Staphylococcus aureus endocarditis has been questioned because of in vitro inactivation by staphylococcal beta-lactamase. Cefazolin, although inactivated in vitro by S. aureus beta-lactamase, was as effective as cephalothin in the treatment of left-sided S. aureus endocarditis in rabbits. Cefazolin (20 mg/kg every 6 or 8 h), cephalothin (40 mg/kg every 6 h), and methicillin (40 mg/kg every 6 h), administered intramuscularly, were compared in the treatment of left-sided endocarditis caused in rabbits by a highly penicillin-resistant strain of S. aureus. The three antibiotics were all effective in reducing titers in vegetations. However, at the dose used, methicillin reduced the titers more rapidly than cephalothin or cefazolin. Cefazolin concentrations in serum were about double those achieved with cephalothin or methicillin. However, cefazolin was only half as active as methicillin and one-eighth as active as cephalothin in vitro in a serum assay. The half life in serum of cefazolin, cephalothin, and methicillin were each about 30 min. Serum bactericidal activities of the three antibiotics were very similar.

Entities:  

Mesh:

Substances:

Year:  1978        PMID: 626493      PMCID: PMC352187          DOI: 10.1128/AAC.13.1.74

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  7 in total

1.  Pharmacology of cefazolin in patients with normal and abnormal renal function.

Authors:  M E Levison; S P Levison; K Ries; D Kaye
Journal:  J Infect Dis       Date:  1973-10       Impact factor: 5.226

2.  Chemotherapy of experimental streptococcal endocarditis. I. Comparison of commonly recommended prophylactic regimens.

Authors:  D T Durack; R G Petersdorf
Journal:  J Clin Invest       Date:  1973-03       Impact factor: 14.808

3.  Inactivation of cefazolin, cephaloridine, and cephalothin by methicillin-sensitive and methicillin-resistant strains of Staphylococcus aureus.

Authors:  C Regamey; R D Libke; E R Engelking; J T Clarke; M M Kirby
Journal:  J Infect Dis       Date:  1975-03       Impact factor: 5.226

4.  A guide to use of antibiotics in patients with renal disease. A table of recommended doses and factors governing serum levels.

Authors:  C M Kunin
Journal:  Ann Intern Med       Date:  1967-07       Impact factor: 25.391

5.  Unsuccessful treatment of staphylococcal endocarditis with cefazolin.

Authors:  R E Bryant; R H Alford
Journal:  JAMA       Date:  1977-02-07       Impact factor: 56.272

6.  Antibiotic synergism in enterococcal endocarditis.

Authors:  J Carrizosa; D Kaye
Journal:  J Lab Clin Med       Date:  1976-07

7.  IN VITRO AND IN VIVO LABORATORY EVALUATION OF CEPHALOGLYCIN AND CEPHALORIDINE.

Authors:  W E WICK; W S BONIECE
Journal:  Appl Microbiol       Date:  1965-03
  7 in total
  11 in total

1.  Characterization of four beta-lactamases produced by Staphylococcus aureus.

Authors:  D J Zygmunt; C W Stratton; D S Kernodle
Journal:  Antimicrob Agents Chemother       Date:  1992-02       Impact factor: 5.191

2.  Efficacy of ceftriaxone and gentamicin given once a day by using human-like pharmacokinetics in treatment of experimental staphylococcal endocarditis.

Authors:  Joan Gavaldà; Pedro López; Teresa Martín; Xavier Gomis; José Luis Ramírez; Carlos Azuaje; Benito Almirante; Albert Pahissa
Journal:  Antimicrob Agents Chemother       Date:  2002-02       Impact factor: 5.191

3.  Is cefazolin inferior to nafcillin for treatment of methicillin-susceptible Staphylococcus aureus bacteremia?

Authors:  Shinwon Lee; Pyoeng Gyun Choe; Kyoung-Ho Song; Sang-Won Park; Hong Bin Kim; Nam Joong Kim; Eui-Chong Kim; Wan Beom Park; Myoung-Don Oh
Journal:  Antimicrob Agents Chemother       Date:  2011-08-08       Impact factor: 5.191

4.  Comparative evaluation of the tolerability of cefazolin and nafcillin for treatment of methicillin-susceptible Staphylococcus aureus infections in the outpatient setting.

Authors:  Ilan Youngster; Erica S Shenoy; David C Hooper; Sandra B Nelson
Journal:  Clin Infect Dis       Date:  2014-04-29       Impact factor: 9.079

5.  Comparison of ceforanide, cefazolin, methicillin, and nafcillin in Staphylococcus aureus endocarditis therapy in rabbits.

Authors:  J Carrizosa; W D Kobasa; D Kaye
Journal:  Antimicrob Agents Chemother       Date:  1980-10       Impact factor: 5.191

6.  Treatment of experimental Staphylococcus aureus abscesses: comparison of cefazolin, cephalothin, cefoxitin, and cefamandole.

Authors:  D Kaye; J N Parsons; J Carrizosa; W D Kobasa
Journal:  Antimicrob Agents Chemother       Date:  1979-02       Impact factor: 5.191

7.  Methicillin distribution in serum and extravascular fluid and its relevance to normal and damaged heart valves.

Authors:  F M Gengo; J J Schentag
Journal:  Antimicrob Agents Chemother       Date:  1981-05       Impact factor: 5.191

8.  Effectiveness of nafcillin, methicillin, and cephalothin in experimental Staphylococcus aureus endocarditis.

Authors:  J Carrizosa; W D Kobasa; D Kaye
Journal:  Antimicrob Agents Chemother       Date:  1979-05       Impact factor: 5.191

9.  Prevalence of a Cefazolin Inoculum Effect Associated with blaZ Gene Types among Methicillin-Susceptible Staphylococcus aureus Isolates from Four Major Medical Centers in Chicago.

Authors:  Sheila K Wang; Annette Gilchrist; Anastasia Loukitcheva; Balbina J Plotkin; Ira M Sigar; Alan E Gross; J Nicholas O'Donnell; Natasha Pettit; Amy Buros; Tristan O'Driscoll; Nathaniel J Rhodes; Cindy Bethel; John Segreti; Angella Charnot-Katsikas; Kamaljit Singh; Marc H Scheetz
Journal:  Antimicrob Agents Chemother       Date:  2018-07-27       Impact factor: 5.191

10.  Cefoperazone treatment of experimental endocarditis.

Authors:  R A Snepar; J Carrizosa; W D Kobasa; D Kaye
Journal:  Antimicrob Agents Chemother       Date:  1981-05       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.